Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries
- 1 September 1998
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (13), 1571-1580
- https://doi.org/10.1097/00002030-199813000-00003
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South AfricaAIDS, 1998
- Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan AfricaAIDS, 1998
- Economic foundations of cost-effectiveness analysisJournal of Health Economics, 1997
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screeningPublished by American Medical Association (AMA) ,1996
- Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country settingPublished by American Medical Association (AMA) ,1996
- Rates of Mother-to-Child Transmission of HIV-1 in Africa, America, and EuropeJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- On what basis should health be discounted?Journal of Health Economics, 1993